Table 2. The results of the feature selection in the competing risk model.
| Levels | Factor | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| Age >80 years | Age | 1.79 (1.79–2.6) | 0.0020 | 1.86 (1.28–2.7) | 0.0012 | |
| Age 60–80 years | Age | 1.22 (1.22–1.61) | 0.1400 | 1.18 (0.9–1.55) | 0.2400 | |
| Age unknown | Age | 24.59 (24.59–31.57) | 0.0000 | 20.31 (12.78–32.26) | 0.0000 | |
| Behavior SCC | Behavior | 1.77 (1.77–3.09) | 0.0440 | 1.76 (1.01–3.07) | 0.0470 | |
| Behavior SCC, keratinizing | Behavior | 1.75 (1.75–3.21) | 0.0730 | 1.8 (0.98–3.3) | 0.0570 | |
| Behavior SCC, non-keratinizing | Behavior | 0.93 (0.93–2.16) | 0.8600 | 0.92 (0.4–2.16) | 0.8600 | |
| Bone metastasis: yes | Bone metastasis | 3.26 (3.26–5.52) | 0.0000 | 3.35 (1.94–5.79) | 0.0000 | |
| Chemotherapy: yes | Chemotherapy | 1 (1–1.26) | 0.9700 | |||
| Grade: Grade II | Grade | 0.88 (0.88–1.55) | 0.6500 | |||
| Grade: Grade III | Grade | 0.89 (0.89–1.58) | 0.6800 | |||
| Grade: Grade IV | Grade | 0.31 (0.31–2.43) | 0.2700 | |||
| Grade: unknown | Grade | 0.72 (0.72–1.31) | 0.2900 | |||
| Income > $60,000 | Income | 1.01 (1.01–1.6) | 0.9700 | |||
| Income $40,000–$60,000 | Income | 0.92 (0.92–1.5) | 0.7300 | |||
| Liver metastasis: yes | Liver metastasis | 1.89 (1.89–4.03) | 0.0980 | |||
| Lung metastasis: unknown | Lung metastasis | 1.15 (1.15–8.46) | 0.8900 | |||
| Lung metastasis: yes | Lung metastasis | 1.59 (1.59–2.52) | 0.0510 | |||
| Marital status: married | Marital status | 0.93 (0.93–1.31) | 0.6800 | |||
| Marital status: other | Marital status | 0.54 (0.54–1.08) | 0.0810 | |||
| Marital status: separated | Marital status | 0.65 (0.65–2.14) | 0.4800 | |||
| Marital status: single | Marital status | 0.96 (0.96–1.41) | 0.8500 | |||
| Marital status: widowed | Marital status | 1.3 (1.3–2.01) | 0.2400 | |||
| Months treatment: >3 | Months treatment | 0.83 (0.83–1.3) | 0.4100 | |||
| Months treatment: unknown | Months treatment | 1.1 (1.1–1.59) | 0.6200 | |||
| Nodes metastasis: unknown | Nodes metastasis | 0.77 (0.77–0.99) | 0.0440 | |||
| Nodes metastasis: yes | Nodes metastasis | 0.77 (0.77–3.18) | 0.7200 | |||
| Nodes positive: yes | Nodes positive | 1.57 (1.57–2.07) | 0.0017 | |||
| Nodes removed: yes | Nodes removed | 0.79 (0.79–1.11) | 0.1700 | |||
| N* staging: N1 | N stage | 1.57 (1.57–2.32) | 0.0220 | |||
| N* staging: N2 | N stage | 1.84 (1.84–2.52) | 0.0001 | |||
| N* staging: N3 | N stage | 1.61 (1.61–2.96) | 0.1200 | |||
| N* staging: NX | N stage | 1.68 (1.68–2.56) | 0.0150 | |||
| Number of malignant: >3 | Number of malignant | 0.23 (0.23–0.93) | 0.0390 | |||
| Primary site: other | Primary site | 2.54 (2.54–4.71) | 0.0030 | 2.34 (1.25–4.38) | 0.0078 | |
| Primary site: PS | Primary site | 1.97 (1.97–3.64) | 0.0310 | 1.79 (0.96–3.33) | 0.0680 | |
| Primary site: PWH | Primary site | 1.96 (1.96–4.06) | 0.0710 | 1.8 (0.87–3.75) | 0.1200 | |
| Primary: yes | Primary | 1.27 (1.27–1.66) | 0.0910 | |||
| Race: black | Race | 0.5 (0.5–0.83) | 0.0080 | 0.56 (0.33–0.95) | 0.0330 | |
| Race: other | Race | 0.71 (0.71–2.08) | 0.5400 | 0.87 (0.29–2.59) | 0.8000 | |
| Race: white | Race | 0.71 (0.71–1.04) | 0.0780 | 0.78 (0.52–1.17) | 0.2200 | |
| Radiation: yes | Radiation | 0.9 (0.9–1.18) | 0.4500 | |||
| Sex: male | Sex | 0.93 (0.93–1.24) | 0.6200 | |||
| Size: >6 cm | Size | 1.51 (1.51–2.42) | 0.0820 | 1.54 (0.96–2.45) | 0.0720 | |
| Size: 3–6 cm | Size | 2.39 (2.39–4.03) | 0.0011 | 2.3 (1.37–3.87) | 0.0017 | |
| Stage group II | Stage group II | 0.91 (0.91–2.35) | 0.8500 | |||
| Stage group III | Stage group III | 1.64 (1.64–3.84) | 0.2500 | |||
| Stage group IV | Stage group IV | 2.31 (2.31–5.14) | 0.0400 | |||
| Stage group II: unknown | Stage group II | 1.89 (1.89–4.38) | 0.1400 | |||
| Summary stage: localized | Summary stage | 0.41 (0.41–0.63) | 0.0000 | |||
| Summary stage: regional | Summary stage | 0.79 (0.79–1.01) | 0.0600 | |||
| Surgery radiation sequence: 2 | Radiation after surgery | 0.83 (0.83–2.02) | 0.6900 | |||
| Surgery radiation sequence: 3 | No radiation | 0.79 (0.79–1.88) | 0.6000 | |||
| Surgery radiation sequence: other | Other | 0.85 (0.85–6.89) | 0.8800 | |||
| Surgery: yes | Surgery | 0.82 (0.82–1.1) | 0.1900 | |||
| Systemic therapy: yes | Systemic therapy | 1.12 (1.12–1.48) | 0.4000 | |||
| T* staging: T2 | T stage | 1.57 (1.57–2.76) | 0.1200 | |||
| T* staging: T3 | T stage | 1.92 (1.92–3.41) | 0.0270 | |||
| T* staging: T4 | T stage | 2.36 (2.36–4.12) | 0.0025 | |||
| T* staging: TX | T stage | 1.14 (1.14–2.42) | 0.7300 | |||
| T* staging: unknown | T stage | 2.02 (2.02–3.74) | 0.0250 | |||
*, TNM staging, TNM groups by 7th edition of the American Joint Committee on Cancer Classifications. SCC, sequamous-cell carcinoma; PS, pyriform sinus; PWH, posterior wall of hypopharynx.